哮喘的遗传学和基因组学指导药物靶点发现的前景
2021/01/28
摘要
哮喘是一种气道炎症性疾病，估计影响全球3.39亿人。大约5%--10%的哮喘患者的症状不能用目前的疗法得到充分控制，并且在开发针对哮喘潜在机制而非抑制症状的药物方面取得的成功很少。在过去的三年中，功能强大的哮喘遗传研究已将独立的哮喘相关遗传基因位点增加到128个。在本系列文章中，我们描述了过去13年间哮喘遗传学的巨大进步，并将哮喘遗传变异与可能的药物靶标相关联。需要进一步的研究来确定哮喘相关的基因变异在患者亚组中的功能意义，并描述他们在其中发挥作用的生物学网络。以基因组学为指导的哮喘药物靶点的发现，可能为重新利用现有的哮喘药物和开发新疗法铺平道路。
The genetics of asthma and the promise of genomics-guided drug target discovery
Zaid W El-Husseini , Reinoud Gosens , Frank Dekker , Gerard H Koppelman
Abstract
Asthma is an inflammatory airway disease that is estimated to affect 339 million people globally. The symptoms of about 5-10% of patients with asthma are not adequately controlled with current therapy, and little success has been achieved in developing drugs that target the underlying mechanisms of asthma rather than suppressing symptoms. Over the past 3 years, well powered genetic studies of asthma have increased the number of independent asthma-associated genetic loci to 128. In this Series paper, we describe the immense progress in asthma genetics over the past 13 years and link asthma genetic variants to possible drug targets. Further studies are needed to establish the functional significance of gene variants associated with asthma in subgroups of patients and to describe the biological networks within which they function. The genomics-guided discovery of plausible drug targets for asthma could pave the way for the repurposing of existing drugs for asthma and the development of new treatments.
哮喘是一种气道炎症性疾病，估计影响全球3.39亿人。大约5%--10%的哮喘患者的症状不能用目前的疗法得到充分控制，并且在开发针对哮喘潜在机制而非抑制症状的药物方面取得的成功很少。在过去的三年中，功能强大的哮喘遗传研究已将独立的哮喘相关遗传基因位点增加到128个。在本系列文章中，我们描述了过去13年间哮喘遗传学的巨大进步，并将哮喘遗传变异与可能的药物靶标相关联。需要进一步的研究来确定哮喘相关的基因变异在患者亚组中的功能意义，并描述他们在其中发挥作用的生物学网络。以基因组学为指导的哮喘药物靶点的发现，可能为重新利用现有的哮喘药物和开发新疗法铺平道路。
(中日友好医院呼吸与危重症医学科 张清 摘译 林江涛 审校)
(Lancet Respir Med. 2020 Oct;8(10):1045-1056. doi: 10.1016/S2213-2600(20)30363-5.)
(Lancet Respir Med. 2020 Oct;8(10):1045-1056. doi: 10.1016/S2213-2600(20)30363-5.)
The genetics of asthma and the promise of genomics-guided drug target discovery
Zaid W El-Husseini , Reinoud Gosens , Frank Dekker , Gerard H Koppelman
Abstract
Asthma is an inflammatory airway disease that is estimated to affect 339 million people globally. The symptoms of about 5-10% of patients with asthma are not adequately controlled with current therapy, and little success has been achieved in developing drugs that target the underlying mechanisms of asthma rather than suppressing symptoms. Over the past 3 years, well powered genetic studies of asthma have increased the number of independent asthma-associated genetic loci to 128. In this Series paper, we describe the immense progress in asthma genetics over the past 13 years and link asthma genetic variants to possible drug targets. Further studies are needed to establish the functional significance of gene variants associated with asthma in subgroups of patients and to describe the biological networks within which they function. The genomics-guided discovery of plausible drug targets for asthma could pave the way for the repurposing of existing drugs for asthma and the development of new treatments.
上一篇：
平衡多数和少数的需求：成人哮喘指南的下一步是什么？
下一篇：
myAirCoach的有效性：一项关于移动健康管理系统的哮喘患者自我管理研究
